Abstract
This thesis focuses on imaging with PET and radiolabeled immune
checkpoint inhibitors to increase the knowledge about these
medicines, their whole body distribution, drug target expression, and
factors determining patient response.
We performed first-in-human studies to assess drug biodistribution, uptake at the drugs target, heterogeneity in target expression and relation to uptake and treatment response.
In this thesis, we demonstrate how ImmunoPET imaging can combine
the target specificity of an antibody with the advantages of PET-based
visualization and quantification. In two reviews and our own work, we
show how this technique is being used in small smart trials to support
drug development and patient selection.
checkpoint inhibitors to increase the knowledge about these
medicines, their whole body distribution, drug target expression, and
factors determining patient response.
We performed first-in-human studies to assess drug biodistribution, uptake at the drugs target, heterogeneity in target expression and relation to uptake and treatment response.
In this thesis, we demonstrate how ImmunoPET imaging can combine
the target specificity of an antibody with the advantages of PET-based
visualization and quantification. In two reviews and our own work, we
show how this technique is being used in small smart trials to support
drug development and patient selection.
| Original language | English |
|---|---|
| Qualification | Doctor of Philosophy |
| Awarding Institution |
|
| Supervisors/Advisors |
|
| Award date | 23-Sep-2021 |
| Place of Publication | [Groningen] |
| Publisher | |
| Print ISBNs | 978-94-6416-679-8 |
| Electronic ISBNs | 978-94-6416-761-0 |
| DOIs | |
| Publication status | Published - 2021 |